01—Abstract
Summary
Summary of the 10-K filed February 22, 2011. Cited figures are marked; the original filing is the authoritative source.
Eli Lilly and Company's 2010 10-K filing highlights a year of 6% revenue growth, reaching $23.08 billiona, driven by key products like Alimta, Cymbalta, and insulin products, alongside a strong performance in its animal health division.
Net income saw a significant increase of 17% to $5.07 billion, with earnings per share rising to $4.58b. However, the report also flags upcoming patent expirations for major products such as Zyprexa (October 2011) and Cymbalta (2013), which are expected to lead to a "rapid and severe decline" in sales due to generic competition, posing a material risk to future financial performance. The company's R&D investment increased to $4.88 billion, reflecting its commitment to developing new medicines, with a robust pipeline across various therapeutic areas including diabetes, oncology, and Alzheimer's disease.
Despite this investment, the company faces ongoing patent challenges and the increasing impact of healthcare reforms and pricing pressures globally. Lilly is actively managing these risks through collaborations and a focus on its patent-protected portfolio, but investors should be aware of the significant headwinds from patent cliffs in the near term.
02—Key points
Key Highlights
- Revenue increased by 6% to $23.08 billion in 2010, driven by strong performance from Alimta, Cymbalta, and insulin products, as well as the animal health segment.
- Net income rose by 17% to $5.07 billion, with earnings per share increasing to $4.58, reflecting effective cost management alongside revenue growth.
- Research and Development (R&D) expenses increased by 13% to $4.88 billion, signaling continued investment in pipeline development for new therapeutic areas.
- Major products like Zyprexa and Cymbalta are facing imminent patent expirations in key markets (e.g., Zyprexa in the US in October 2011), posing a significant risk of sales decline due to generic competition.
- The company is navigating the complexities of U.S. healthcare reform, which is expected to reduce revenue by $400 million to $500 million in 2011 due to increased rebates and fees.
- Lilly faces ongoing patent litigation for several key products, including Alimta, Cymbalta, and Strattera, with the outcomes having the potential for material impact.
- The company's financial condition remains strong, with cash and cash equivalents totaling $5.99 billion at the end of 2010, providing flexibility for operations and strategic initiatives.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2010filed February 22, 2011Financial Statements
FY2010 against FY2009
| Line item | FY2010FY2009 | Change |
|---|---|---|
| Revenue | $23.08B$21.84B | +5.7% |
| Cost of Revenue | $4.37B$4.25B | +2.8% |
| Gross Profit | $18.71B$17.59B | +6.4% |
| R&D Expenses | $4.88B$4.33B | +12.9% |
| SG&A Expenses | $7.05B$6.89B | +2.3% |
| Interest Expense | $185.50M$261.30M | −29.0% |
| Net Income | $5.07B$4.33B | +17.1% |
| EPS (Basic) | $4.58$3.94 | +16.2% |
| EPS (Diluted) | $4.58$3.94 | +16.2% |
| Shares Outstanding (Basic) | 1.11B1.10B | +0.7% |
| Shares Outstanding (Diluted) | 1.11B1.10B | +0.7% |
05—Questions
Frequently Asked Questions
What are the key revenue drivers for Eli Lilly in 2010?
Eli Lilly's revenue drivers in 2010 included strong performance from Alimta, Cymbalta, its insulin products (Humalog and Humulin), Cialis, and its animal health products. These were partially offset by a decline in Gemzar revenue.
What is the primary risk highlighted in the 2010 10-K filing for investors?
The most significant risk highlighted for investors is the upcoming loss of patent exclusivity for major products like Zyprexa (in October 2011 in the U.S.) and Cymbalta (in 2013). This is expected to lead to a substantial decline in sales due to generic competition, which the company terms a "rapid and severe decline" and a "material adverse effect" on its results.
How is Eli Lilly addressing the impact of upcoming patent expirations?
Eli Lilly plans to partially mitigate the impact of patent expirations by focusing on growth from its other patent-protected products, expanding in emerging markets and Japan, and growing its animal health business. The company is also heavily investing in R&D to build its pipeline of new medicines.
What is the company's stance on research and development investment?
Eli Lilly views R&D investment as critical to its long-term competitiveness. In 2010, R&D expenses increased by 13% to $4.88 billion, reflecting continued investment in a robust pipeline across therapeutic areas such as diabetes, oncology, and Alzheimer's disease, despite the inherent risks and costs associated with drug development.
06—Continue